Interpace Biosciences, Inc. (MUN:PF42)

Market Cap	46.97M +787.7%
Revenue (ttm)	32.98M -6.1%
Net Income	20.93M -44.6%
EPS	0.75 -93.6%
Shares Out	n/a
PE Ratio	2.24
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	1.060
Previous Close	1.060
Day's Range	1.060 - 1.060
52-Week Range	1.060 - 1.510
Beta	n/a
RSI	100.00
Earnings Date	Apr 7, 2026

About Interpace Biosciences

Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test for the diagnosis of pancreaticobiliary cancers using its proprietary PathFinderTG platform; PanDNA, a molecular only version of PancraGEN; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. The company also provides ThyraMIR v2, which assesses thyroid nodules for malignancy ri...

• Industry: Medical Laboratories
• Founded: 1986
• Employees: 111
• Stock Exchange: Munich Stock Exchange
• Ticker Symbol: PF42

Financial Performance

In 2024, Interpace Biosciences's revenue was $46.93 million, an increase of 17.21% compared to the previous year's $40.04 million. Earnings were $6.24 million, an increase of 219.24%.

Financial numbers in USD